September 2026
1. FILOMIA S, Del Buono MG, Saponara G, Aurigemma C, et al
   Fluoropyrimidine Cardiotoxicity: Role of Uridine Triacetate and Pharmacogenomic Insights from a Case of 5-FU-Induced Cardiogenic Shock.
   J Cardiovasc Pharmacol. 2026;88:216-222.
   

   >> Share

   
   August 2026
2. APOSTOLOS A, Panoulas V
   Triple Antithrombotic Therapy for the Prevention of Left Ventricular Thrombus Following Anterior ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis.
   J Cardiovasc Pharmacol. 2026 Aug 20. doi: 10.1097/FJC.0000000000001872.
   

   >> Share

   
   
3. STUTZ F MOREIRA G, Barbosa LM, Lima JO
   Cardiovascular and Thromboembolic Risk With Upadacitinib in Spondyloarthritis and Inflammatory Bowel Disease: A Meta-Analysis of Randomized Controlled Trials.
   J Cardiovasc Pharmacol. 2026 Aug 19. doi: 10.1097/FJC.0000000000001873.
   

   >> Share

   
   
4. YANG J, Meng K, Wu G, Liang J, et al
   Empagliflozin Reduces Post-Myocardial Infarction Inflammation via BDH1/beta-Hydroxybutyrate-Mediated NF-kappaB Modulation in Macrophages and the Heart.
   J Cardiovasc Pharmacol. 2026 Aug 12. doi: 10.1097/FJC.0000000000001870.
   

   >> Share

   
   
5. KIRDEEV A, Burkin K, Vorobev A, Zbirovskaya E, et al
   Machine Learning Models Integrating CYP2C19 Genotypes for Long-Term Risk Prediction and Personalized Antiplatelet Therapy Selection in Myocardial Infarction.
   J Cardiovasc Pharmacol. 2026 Aug 12. doi: 10.1097/FJC.0000000000001871.
   

   >> Share

   
   July 2026
6. DE FILIPPO O, Bruno F, Giacobbe F, Beccuti G, et al
   Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.
   J Cardiovasc Pharmacol. 2026 Jul 28. doi: 10.1097/FJC.0000000000001862.
   

   >> Share

   
   
7. MILAN RR, Jimenez Castellanos MS, Doniz Viveros AD, Yusufzai MO, et al
   Efficacy and safety of CETP inhibitors in patients with atherosclerotic cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.
   J Cardiovasc Pharmacol. 2026 Jul 6. doi: 10.1097/FJC.0000000000001856.
   

   >> Share

   
   
8. PUCHONGMART C, Rodriguez CC, Soliman D, Shotelersuk V, et al
   Pharmacologic Management of Type 2 Myocardial Infarction: An Underdefined Frontier.
   J Cardiovasc Pharmacol. 2026 Jul 6. doi: 10.1097/FJC.0000000000001855.
   

   >> Share

   
   
9. ZHENG W, Zhou Y, Ye B, Hu S, et al
   SGLT2 Inhibitors Attenuate Neutrophil-Mediated Endothelial Injury in Coronary Artery Disease With Type 2 Diabetes Mellitus Through a GREM1-Associated Smad Signaling Axis.
   J Cardiovasc Pharmacol. 2026;88:25-35.
   

   >> Share

   
   June 2026
10. CHEN Z, Li G, Tang X, Liu X, et al
    Cardiovascular Adverse Events Associated with Immune Checkpoint Inhibitors from the Perspective of Gut Microecology: Potential Roles and Research Advances of the Gut Microbiota.
    J Cardiovasc Pharmacol. 2026 Jun 5. doi: 10.1097/FJC.0000000000001842.
    

    >> Share

    
    May 2026
11. BOVA R, Bastings J, Betti M, Snik C, et al
    Design and Rationale of the COMMIT-LAD Registry: A Comprehensive Analysis of Medical and Invasive Treatment Strategies for Patients With Significant Left Anterior Descending Artery Disease (COMMIT-LAD).
    J Cardiovasc Pharmacol. 2026;87:357-363.
    

    >> Share

    
    April 2026
12. KHAN M, Janjua MAH, Akhtar SMM, Al-Qaraghuli A, et al
    Efficacy and Safety of Aspirin-free versus Aspirin-based Strategies in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2026;87:209-218.
    

    >> Share

    
    
13. AKSOY F, Savran M, Uysal D, Bagci A, et al
    Cannabidiol Protects the Heart From Ischemia-Reperfusion Injury Through SIRT-1/PGC-1alpha Activation and Nuclear Factor Kappa B Modulation: Experimental Insights.
    J Cardiovasc Pharmacol. 2026;87:270-282.
    

    >> Share

    
    March 2026
14. HILVO M, Witoslawska A, Laaperi M, Jylha A, et al
    Ceramide-phospholipid risk score associates with cardiovascular events and is lowered by atorvastatin, simvastatin and anti-PCSK9 treatments.
    J Cardiovasc Pharmacol. 2026 Mar 12. doi: 10.1097/FJC.0000000000001817.
    

    >> Share

    
    
15. TAN J, Gu J
    The Multifaceted Role of Angiopoietin-Like Proteins in Coronary Heart Disease: From Molecular Mechanisms to Clinical Translation.
    J Cardiovasc Pharmacol. 2026 Mar 2. doi: 10.1097/FJC.0000000000001815.
    

    >> Share

    
    February 2026
16. WEBER B, McCarty D, Robar C, Fainberg U, et al
    Patients' and Healthcare Professionals' Perspectives in Managing Atherosclerotic Cardiovascular Disease: A Survey of Unmet Needs and Perceived Benefits of Treating Systemic Inflammation in Cardiovascular Diseases.
    J Cardiovasc Pharmacol. 2026 Feb 25. doi: 10.1097/FJC.0000000000001800.
    

    >> Share

    
    
17. GIBSON CM, Escano AK, Hobe KD, Brody ER, et al
    Safety and effectiveness of somatostatin and analogues on chest tube output after coronary artery bypass grafting: A scoping review.
    J Cardiovasc Pharmacol. 2026 Feb 19. doi: 10.1097/FJC.0000000000001810.
    

    >> Share

    
    
18. GIORDANO S, Morello A, Biondi-Zoccai G, Corcione N, et al
    When Phenotyping Is the Intervention: Personlized Treatment of Diffuse Coronary Artery Disease.
    J Cardiovasc Pharmacol. 2026 Feb 18. doi: 10.1097/FJC.0000000000001809.
    

    >> Share

    
    
19. BIONDI-ZOCCAI G, Frati G, Booz GW
    Closing the translational gap in cardiovascular artificial intelligence: from drug discovery to evidence synthesis.
    J Cardiovasc Pharmacol. 2026 Feb 18. doi: 10.1097/FJC.0000000000001808.
    

    >> Share

    
    
20. WANG G, Luo Y, Song S, Li X, et al
    Role of the Gut Microbiome in Modulating Interactions Between beta-Lactam Antibiotics and Statins in Coronary Heart Disease.
    J Cardiovasc Pharmacol. 2026 Feb 17. doi: 10.1097/FJC.0000000000001805.
    

    >> Share

    
    
21. KIM HL, Lee B, Im S
    The comparative effects of S-amlodipine versus racemic amlodipine on long-term cardiovascular outcomes in subjects with hypertension: a nationwide population-based cohort study.
    J Cardiovasc Pharmacol. 2026 Feb 9. doi: 10.1097/FJC.0000000000001793.
    

    >> Share

    
    
22. ABDELHAMID A, Nasrallah D, Al-Haneedi Y, Ahmed E, et al
    The Emerging Role of Artificial Intelligence in Drug Discovery and Development: Implications for Cardiovascular Pharmacology.
    J Cardiovasc Pharmacol. 2026 Feb 3. doi: 10.1097/FJC.0000000000001803.
    

    >> Share

    
    January 2026
23. KIANFAR T, Fallah M, Ramezani F, Rakhshan K, et al
    Dapagliflozin reduces myocardial injuries through modulation of H3K27me3 and SIRT1 in the male rat model of myocardial ischemia reperfusion.
    J Cardiovasc Pharmacol. 2026 Jan 22. doi: 10.1097/FJC.0000000000001795.
    

    >> Share

    
    
24. KUMAR S, Thotakura S, Kearney KE, Lombardi WL, et al
    Protamine for Coronary Perforation in Chronic Total Occlusion Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2026 Jan 22. doi: 10.1097/FJC.0000000000001791.
    

    >> Share

    
    December 2025
25. TOLU-AKINNAWO OZ, Greek A, Jaamour D, Azeez HA, et al
    Individualized Cardiovascular Therapeutics via Artificial Intelligence-Powered Cardiovascular Imaging.
    J Cardiovasc Pharmacol. 2025 Dec 24. doi: 10.1097/FJC.0000000000001788.
    

    >> Share

    
    
26. BARBOSA LM, Rodrigues Oliveira VM, Nunes MDCP, Moreira HG, et al
    Direct Oral Anticoagulants versus Warfarin on Coronary Plaque in Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2025 Dec 16. doi: 10.1097/FJC.0000000000001787.
    

    >> Share

    
    November 2025
27. TEPERIKIDIS L, Boulmpou A, Chownk M, Jagdale R, et al
    Colchicine for Major Adverse Cardiovascular Events: An Updated ChatGPT-Assisted Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2025 Nov 25. doi: 10.1097/FJC.0000000000001780.
    

    >> Share

    
    October 2025
28. KHATAMI S, Faghihi M, Zarrin A, Sarveazad A, et al
    Cardioprotective Effects of Apelin in Myocardial Ischemia/Reperfusion Injury: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2025 Oct 28. doi: 10.1097/FJC.0000000000001773.
    

    >> Share

    
    
29. LI J, Li X, Chen Y, Fang L, et al
    Cardioprotective effects of soluble guanylate cyclase and its alpha1 subunit on myocardial ischemia/reperfusion injury via the PGC-1alpha/UCP2 pathway.
    J Cardiovasc Pharmacol. 2025 Oct 13. doi: 10.1097/FJC.0000000000001765.
    

    >> Share

    
    September 2025
30. SALLOUM FN, Raucci FJ
    Remodeling Cardiovascular Research: Ready to Sacrifice Animal Models?
    J Cardiovasc Pharmacol. 2025 Sep 18. doi: 10.1097/FJC.0000000000001759.
    

    >> Share

    
    August 2025
31. MA M, Xu C, Zhou H, Zhou Y, et al
    Lactylation in Cardiovascular Diseases: Epigenetic Mechanisms and Therapeutic Potential.
    J Cardiovasc Pharmacol. 2025 Aug 15. doi: 10.1097/FJC.0000000000001751.
    

    >> Share

    
    
32. BIONDI-ZOCCAI G, Frati G, Carnevale R, Booz GW, et al
    Human-Based Technologies in Cardiovascular Pharmacology Research.
    J Cardiovasc Pharmacol. 2025 Aug 5. doi: 10.1097/FJC.0000000000001745.
    

    >> Share

    
    July 2025
33. MARCHETTA M, Golino M, Markley JD, Abbate A, et al
    Rare but Severe Cardiovascular Complications of SARS-CoV-2 Vaccination: A Call for Awareness.
    J Cardiovasc Pharmacol. 2025 Jul 24. doi: 10.1097/FJC.0000000000001740.
    

    >> Share

    
    
34. BIONDI-ZOCCAI G, Vassiliou VS, Palumbo MC, Booz GW, et al
    Phthalates and Cardiovascular Risk: A Call for Awareness in Clinical Practice.
    J Cardiovasc Pharmacol. 2025 Jul 18. doi: 10.1097/FJC.0000000000001732.
    

    >> Share

    
    
35. FAGHIHI M, Ahmadi-Beni M, Houshmand F
    Role of Muscarinic Acetylcholine Receptors in Oxytocin-Induced Cardioprotection Against Ischemia-Reperfusion Injury in Rats.
    J Cardiovasc Pharmacol. 2025;86:109-117.
    

    >> Share

    
    May 2025
36. ZHANG J, Chen X, Wan C
    Aerobic exercise rehabilitation training alleviates skeletal muscle atrophy caused by heart failure in mice through the SIRT1/PGC-1alpha pathway.
    J Cardiovasc Pharmacol. 2025 May 28. doi: 10.1097/FJC.0000000000001722.
    

    >> Share

    
    
37. BAHARDOUST M, Yarahmadi D, Aghakhani Z, Mahdi Kakoienejad M, et al
    Comparison of short-term treatment with atorvastatin versus rosuvastatin for preventing contrast-associated acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention: a systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2025 May 14. doi: 10.1097/FJC.0000000000001718.
    

    >> Share

    
    
38. BURNETT H, Cichewicz A, Natani H, Bhowmik D, et al
    Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis.
    J Cardiovasc Pharmacol. 2025 May 13. doi: 10.1097/FJC.0000000000001712.
    

    >> Share

    
    April 2025
39. ZHANG C, Du Z, Chen R, Liu X, et al
    Gene- and cell-based therapy in cardiovascular diseases.
    J Cardiovasc Pharmacol. 2025 Apr 30. doi: 10.1097/FJC.0000000000001707.
    

    >> Share

    
    
40. CAPPANNOLI L, Fracassi F, Aurigemma C, Romagnoli E, et al
    COLCHICINE IN ACUTE CORONARY SYNDROMES: A META-ANALYSIS OF 12.602 PATIENTS.
    J Cardiovasc Pharmacol. 2025 Apr 28. doi: 10.1097/FJC.0000000000001706.
    

    >> Share

    
    
41. ABBATE A, Biondi-Zoccai G, Altara R, Booz GW, et al
    Changes for 2025 at Journal of Cardiovascular Pharmacology: Introducing Our Junior Associate Editors, Podcasts, Feature, and New Board Members.
    J Cardiovasc Pharmacol. 2025;85:239-242.
    

    >> Share

    
    March 2025
42. SADEGHIPOUR P, Talasaz AH, Rashedi S, Jamalkhani S, et al
    A Multifaceted Intervention to Mitigate the Adverse Cardiovascular Effects of Air Pollution: A Feasibility Randomized Controlled Trial.
    J Cardiovasc Pharmacol. 2025 Mar 18. doi: 10.1097/FJC.0000000000001691.
    

    >> Share

    
    February 2025
43. BIONDI-ZOCCAI G, Weber BN, Abbate A, Booz GW, et al
    Cardiac Immunotherapy, Immuno-Cardiology and the Future of Cardiovascular Pharmacology.
    J Cardiovasc Pharmacol. 2025 Feb 27. doi: 10.1097/FJC.0000000000001687.
    

    >> Share

    
    
44. GRAGNANO F, Calabro P, Angiolillo DJ
    Deciphering the Role of In-hospital Bleeding in Acute Coronary Syndromes.
    J Cardiovasc Pharmacol. 2025 Feb 17. doi: 10.1097/FJC.0000000000001685.
    

    >> Share

    
    
45. PEPE M, Tritto R, Napoli G, Giordano S, et al
    Role of Indobufen in coronary artery disease: the story of a neglected drug. A systematic review.
    J Cardiovasc Pharmacol. 2025 Feb 11. doi: 10.1097/FJC.0000000000001681.
    

    >> Share

    
    
46. SPADAFORA L, Betti M, D'Ascenzo F, De Ferrari G, et al
    Impact of In-Hospital Bleeding on Post-Discharge Therapies and Prognosis in Acute Coronary Syndromes.
    J Cardiovasc Pharmacol. 2025 Feb 10. doi: 10.1097/FJC.0000000000001678.
    

    >> Share

    
    
47. ZHANG K, He C, Tong Y, He Y, et al
    Relationship between ALDH2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.
    J Cardiovasc Pharmacol. 2025 Feb 10. doi: 10.1097/FJC.0000000000001682.
    

    >> Share

    
    
48. GALATI G, Germanova O
    Mineralocorticoid receptor antagonists in end-stage renal disease under renal replacement therapies: bridging the gap between cardiovascular and systemic benefit, from heart failure to myocardial infarction.
    J Cardiovasc Pharmacol. 2025 Feb 6. doi: 10.1097/FJC.0000000000001677.
    

    >> Share

    
    
49. ZHAO C, Fu J, Wang Y, Zhou Y, et al
    Latest evidence and perspectives of Panax notoginseng extracts and preparations for the treatment of cardiovascular diseases: a review.
    J Cardiovasc Pharmacol. 2025 Feb 4. doi: 10.1097/FJC.0000000000001670.
    

    >> Share

    
    January 2025
50. BONAVENTURA A, Potere N, Liberale L, Kraler S, et al
    Colchicine in coronary artery disease: Where do we stand?
    J Cardiovasc Pharmacol. 2025 Jan 23. doi: 10.1097/FJC.0000000000001672.
    

    >> Share

    
    
51. BIONDI-ZOCCAI G, Frati G, Peruzzi M, Bernardi M, et al
    Patient reported outcome measures in cardiovascular research and care: PRO(M)s and CONS.
    J Cardiovasc Pharmacol. 2025 Jan 23. doi: 10.1097/FJC.0000000000001669.
    

    >> Share

    
    
52. ABBATE A, Biondi-Zoccai G, Altara R, Booz GW, et al
    Changes for 2025 at Journal of Cardiovascular Pharmacology: Introducing Our Junior Associate Editors, Podcasts, Feature, and New Board Members.
    J Cardiovasc Pharmacol. 2025 Jan 21. doi: 10.1097/FJC.0000000000001673.
    

    >> Share

    
    
53. ANTO S, Sun C, O'Rourke ST
    Activation of APJ Receptors by CMF-019, But Not Apelin, Causes Endothelium-Dependent Relaxation of Spontaneously Hypertensive Rat Coronary Arteries.
    J Cardiovasc Pharmacol. 2025 Jan 21. doi: 10.1097/FJC.0000000000001671.
    

    >> Share

    
    
54. SADLER M, Madaudo C, Cannata A, Bromage D, et al
    IL-1 blockade in myocardial infarction and its efficacy in patients with complex coronary artery disease. Another brick in the wall.
    J Cardiovasc Pharmacol. 2025 Jan 2. doi: 10.1097/FJC.0000000000001666.
    

    >> Share

    
    December 2024
55. JALLORINA A, Vij K, Wan L, Thomas J, et al
    A Decadal Exploration of Cutaneous Adverse Effects of FDA-Approved Cardiovascular Medications: Insights from 2013 to 2023.
    J Cardiovasc Pharmacol. 2024 Dec 5. doi: 10.1097/FJC.0000000000001660.
    

    >> Share

    
    
56. ABBATE A, Van Tassell B, Bogin V, Markley R, et al
    Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.
    J Cardiovasc Pharmacol. 2024;84:565-577.
    

    >> Share

    
    November 2024
57. YANJUAN L, Shuangyou D, Ying W, Xing C, et al
    The research progress: Cuproptosis and copper metabolism in regulating cardiovascular diseases.
    J Cardiovasc Pharmacol. 2024 Nov 15. doi: 10.1097/FJC.0000000000001653.
    

    >> Share

    
    
58. DENICOLAI M, Morello M, Golino M, Corna G, et al
    Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial Infarction Across the Spectrum of Coronary Artery Disease Complexity.
    J Cardiovasc Pharmacol. 2024 Nov 12. doi: 10.1097/FJC.0000000000001652.
    

    >> Share

    
    
59. GU N, Chen P, Wang X, Shen C, et al
    Association Between the Neutrophil-to-Lymphocyte Ratio and in-Stent Neoatherosclerosis and Plaque Vulnerability: An Optical Coherence Tomography Study.
    J Cardiovasc Pharmacol. 2024;84:506-514.
    

    >> Share

    
    October 2024
60. TIAN RZ, Zhuang DL, Vong CT, He X, et al
    Role of autophagy in myocardial remodeling after myocardial infarction.
    J Cardiovasc Pharmacol. 2024 Oct 25. doi: 10.1097/FJC.0000000000001646.
    

    >> Share

    
    
61. RUBAIY HN
    Canonical Transient Receptor Potential (TRPC) Channels in Cardiovascular Pathology and their Modulators.
    J Cardiovasc Pharmacol. 2024 Oct 15. doi: 10.1097/FJC.0000000000001643.
    

    >> Share

    
    
62. ABBATE A, Van Tassell B, Bogin V, Markley R, et al
    Interleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment elevation myocardial infarction (STEMI): secondary endpoints from an international, double blind, randomized, placebo-controlled, phase IIa study.
    J Cardiovasc Pharmacol. 2024 Oct 2. doi: 10.1097/FJC.0000000000001635.
    

    >> Share

    
    September 2024
63. RUSSO F, Palma A, Cacciatore S, Tomarelli E, et al
    Rethinking beta-blockers after ST-elevation myocardial infarction: essential for some, questionable for others.
    J Cardiovasc Pharmacol. 2024 Sep 6. doi: 10.1097/FJC.0000000000001632.
    

    >> Share

    
    
64. HUANG HM, Ran FY, Chen J, Shen YS, et al
    Outcomes of Ticagrelor Versus High-dose Clopidogrel in CYP2C19 Intermediate Metabolizer Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes.
    J Cardiovasc Pharmacol. 2024;84:347-355.
    

    >> Share

    
    
65. LI YY, Zhong XJ, Luo JT, Zeng CM, et al
    Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China.
    J Cardiovasc Pharmacol. 2024;84:331-339.
    

    >> Share

    
    
66. BABIKER F, Al-Kouh A
    Immunoglobulin-Mediated Cardiac Protection From Ischemia/Reperfusion Injury in Diabetic Rats Is Associated With Endothelial Nitric Oxide Synthase/Glucose Transporter-4 Signaling Pathway.
    J Cardiovasc Pharmacol. 2024;84:319-330.
    

    >> Share

    
    August 2024
67. GIANNINO G, Giacobbe F, Annone U, Ravetti E, et al
    Impact of adherence to beta-blockers in all-comers ST-segment elevation myocardial infarction (STEMI) patients and according to left ventricular ejection fraction (LVEF) at discharge: results from the real-world registry FAST-STEMI.
    J Cardiovasc Pharmacol. 2024 Aug 29. doi: 10.1097/FJC.0000000000001627.
    

    >> Share

    
    
68. SHI J, Guan B, Gong M, He X, et al
    Kirenol alleviates inflammation and oxidative stress to improve myocardial ischemia/reperfusion injury in rats.
    J Cardiovasc Pharmacol. 2024 Aug 22. doi: 10.1097/FJC.0000000000001626.
    

    >> Share

    
    
69. DEL BUONO MG, La Vecchia G, D'Aiello A, Pedicino D, et al
    Clinical Characteristics, Management, and Outcomes in Cardiogenic Shock: Insights From a High-Volume Italian Cardiac Intensive Care Unit.
    J Cardiovasc Pharmacol. 2024;84:210-219.
    

    >> Share

    
    
70. RUSSO V, Fabiani D, Imbalzano E, De Michele M, et al
    Clinical Performance and Persistence on Dual Pathway Inhibition with Rivaroxaban and Aspirin in Real-World Setting.
    J Cardiovasc Pharmacol. 2024;84:170-174.
    

    >> Share

    
    
71. DENG HW, Ye ZM, Hu RT, Qin C, et al
    The Role of Long Noncoding RNAs in Vascular Smooth Muscle Cell Phenotype and the Pathogenesis of Cardiovascular and Cerebrovascular Aneurysms.
    J Cardiovasc Pharmacol. 2024;84:125-135.
    

    >> Share

    
    July 2024
72. DEL BUONO MG, La Vecchia G, Angiolillo DJ
    Antithrombotic treatment regimens in patients undergoing percutaneous coronary revascularization requiring oral anticoagulation: what real-world evidence shows us.
    J Cardiovasc Pharmacol. 2024 Jul 29. doi: 10.1097/FJC.0000000000001619.
    

    >> Share

    
    
73. WRIGHT CX, Feher A
    From Risk to Resilience: improved outcomes after myocardial infarction in patients with Sjogren's syndrome.
    J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001615.
    

    >> Share

    
    
74. ZHANG J, Xiong X, Li J, Luo C, et al
    Valtrate suppresses TNFSF14-mediated arrhythmia after myocardial ischemia-reperfusion via inducing N-linked glycosylation of LTbetaR to regulate MGA/MAX/c-Myc/Cx43.
    J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001613.
    

    >> Share

    
    
75. SCIAHBASI A, De Rosa S, Gargiulo G, Giacoppo D, et al
    Management of patients treated with oral anticoagulant therapy undergoing percutaneous coronary intervention with stent implantation: the PERSEO Registry.
    J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001607.
    

    >> Share

    
    
76. LINGYAN Z, Zijia H, Ya Z, Ying Z, et al
    Cardiovascular outcomes of SGLT-2 Inhibitors Across BMI Spectrum in Heart Failure Patients: An Updated Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2024 Jul 8. doi: 10.1097/FJC.0000000000001610.
    

    >> Share

    
    
77. KARAKASIS P, Patoulias D, Giannakoulas G, Fragakis N, et al
    Are We Ready for Expanding the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Myocardial Infarction?
    J Cardiovasc Pharmacol. 2024;84:26-28.
    

    >> Share

    
    
78. ZHANG X, Sun G, Li Z, Gao W, et al
    Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Acute Myocardial Infarction With or Without Type 2 Diabetes: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2024;84:18-25.
    

    >> Share

    
    
79. SIKORSKA M, Chmiel J, Papuga-Szela E, Broniatowska E, et al
    Apixaban Versus Vitamin K Antagonists in Patients With Antiphospholipid Syndrome: A Cohort Study.
    J Cardiovasc Pharmacol. 2024;84:36-44.
    

    >> Share

    
    June 2024
80. HSIAO BY
    Sjogren syndrome and outcomes of acute myocardial infarction: A propensity-score matched analysis of the Nationwide Inpatient Sample 2005-2018.
    J Cardiovasc Pharmacol. 2024 Jun 19. doi: 10.1097/FJC.0000000000001603.
    

    >> Share

    
    
81. BRUOHA S, Galli M, Sabouret P, Yosefy C, et al
    Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and Potential Therapeutic Strategies-A Review.
    J Cardiovasc Pharmacol. 2024;83:547-556.
    

    >> Share

    
    
82. ZHANG W, Zhang W, Gu N, Qiu Z, et al
    Naturally Occurring Atherosclerosis Progression and In-stent Restenosis: Exploring Histomorphologic Associations Using Optical Coherence Tomography.
    J Cardiovasc Pharmacol. 2024;83:646-654.
    

    >> Share

    
    May 2024
83. ROMEO FJ
    Dual Pathway Inhibition in Stable Cardiovascular Disease: It Takes Two to Tango!
    J Cardiovasc Pharmacol. 2024 May 31. doi: 10.1097/FJC.0000000000001599.
    

    >> Share

    
    
84. HU D, Qin D, Kuang J, Yang Y, et al
    Metformin-induced PCSK9 inhibition further decreases LDL-C following statin treatment in patients with coronary artery disease and without diabetes.
    J Cardiovasc Pharmacol. 2024 May 21. doi: 10.1097/FJC.0000000000001592.
    

    >> Share

    
    
85. LUZ DE CASTRO A, Ortiz VD, Hickmann AR, Lacerda DS, et al
    EFFECTS OF PTEROSTILBENE ON HEART AND LUNG OXIDATIVE STRESS PARAMETERS IN TWO EXPERIMENTAL MODELS OF CARDIOVASCULAR DISEASE: MYOCARDIAL INFARCTION AND PULMONARY ARTERIAL HYPERTENSION.
    J Cardiovasc Pharmacol. 2024 May 4. doi: 10.1097/FJC.0000000000001572.
    

    >> Share

    
    
86. ZANG G, Chen Y, Guo G, Wan A, et al
    Protective Effect of CD137 Deficiency Against Postinfarction Cardiac Fibrosis and Adverse Cardiac Remodeling by ERK1/2 Signaling Pathways.
    J Cardiovasc Pharmacol. 2024;83:446-456.
    

    >> Share

    
    April 2024
87. LU B, Feng Z, Wang Y, Liao J, et al
    N-n-butyl haloperidol iodide mitigates myocardial ischemia/reperfusion injury through activation of SIRT1-Nrf2 signaling loop.
    J Cardiovasc Pharmacol. 2024 Apr 2. doi: 10.1097/FJC.0000000000001550.
    

    >> Share

    
    
88. ZHANG M, Peng W, Yin S, Zhao Y, et al
    Nondual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Before Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2024;83:297-305.
    

    >> Share

    
    March 2024
89. SIMEONE B, Rocco E, Biondi-Zoccai G, Versaci F, et al
    N-Acetylcysteine: The Next Best Thing for Cardiovascular Interventions and Surgery?
    J Cardiovasc Pharmacol. 2024 Mar 14. doi: 10.1097/FJC.0000000000001558.
    

    >> Share

    
    
90. GAO L, Wang Q, Li MY, Zhang MM, et al
    A mechanism for the treatment of cardiovascular and renal disease.
    J Cardiovasc Pharmacol. 2024 Mar 14. doi: 10.1097/FJC.0000000000001562.
    

    >> Share

    
    
91. MARTINEZ NAYA N, Toldo S, Abbate A
    Colchicine Leads the Charge in Post-percutaneous Coronary Intervention Anti-inflammatory Defense.
    J Cardiovasc Pharmacol. 2024;83:231-233.
    

    >> Share

    
    February 2024
92. RT W
    Oral Oncolytics and Cardiovascular Risk Management and Monitoring: Erratum.
    J Cardiovasc Pharmacol. 2024 Feb 15. doi: 10.1097/FJC.0000000000001500.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share